Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
5.3 ^USD	-2.21%		-5.53%	-41.89%

12/06	Cytek Biosciences to Seek M&A	CI
12/06	Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM

Cytek Biosciences, Inc. announces an Equity Buyback for $50 million worth of its shares.

June 06, 2024 at 05:30 pm IST

Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program is valid till December 31, 2024.

Latest news about Cytek Biosciences, Inc.

Cytek Biosciences to Seek M&A	12/06	CI
Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM	12/06
Cytek Biosciences Board Approves $50 Million Share Buyback Plan	06/06	MT
Cytek Biosciences, Inc. announces an Equity Buyback for $50 million worth of its shares.	06/06	CI
Cytek Biosciences, Inc. authorizes a Buyback Plan.	06/06	CI
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	29/05	MT
Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China	29/05	MT
Cytek Biosciences, Inc. Adds Ability to Detect Subcellular Particles to Its Cell Analysis Systems	21/05	CI
Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating	13/05	MT
Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	09/05	MT
Transcript : Cytek Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024	09/05
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024	09/05	CI
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	20/03	MT
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance	19/03	MT
Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics	19/03	CI
Cytek Biosciences, Inc. Announces CFO Changes	19/03	CI
Cytek Biosciences Unveils New Manufacturing Facility in Wuxi, China	08/03	MT
Cytek Biosciences, Inc. Opens A New 50,000-Square-Foot Facility in Wuxi, China	08/03	CI
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	06/03	MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.	01/03	CI
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024	01/03	CI
Cytek Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Transcript : Cytek Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02
Cytek Biosciences Agrees to Flow Cytometry Collaboration With Centre for Genomic Regulation, Pompeu Fabra University	18/01	MT

Chart Cytek Biosciences, Inc.

Duration

Period

More charts

Company Profile

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Sector

Advanced Medical Equipment & Technology

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cytek Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.3 USD

Average target price

9.5 USD

Spread / Average Target

+79.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYTEK BIOSCIENCES, INC.	-41.89%	696M
THERMO FISHER SCIENTIFIC	+5.16%	213B
DANAHER CORPORATION	+9.62%	188B
INTUITIVE SURGICAL, INC.	+31.18%	157B
BOSTON SCIENTIFIC CORPORATION	+33.37%	113B
SIEMENS HEALTHINEERS AG	+3.65%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+20.08%	55.17B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.51%	49.1B
AGILENT TECHNOLOGIES, INC.	-4.27%	38.83B
GE HEALTHCARE TECHNOLOGIES INC.	+0.88%	35.6B

Other Advanced Medical Equipment & Technology